JP2019501125A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501125A5 JP2019501125A5 JP2018525654A JP2018525654A JP2019501125A5 JP 2019501125 A5 JP2019501125 A5 JP 2019501125A5 JP 2018525654 A JP2018525654 A JP 2018525654A JP 2018525654 A JP2018525654 A JP 2018525654A JP 2019501125 A5 JP2019501125 A5 JP 2019501125A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halo
- heteroaryl
- substituted
- bicyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *C1=CC(N(*)*)=I[n]2c1ncc2C(N*)=O Chemical compound *C1=CC(N(*)*)=I[n]2c1ncc2C(N*)=O 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562256784P | 2015-11-18 | 2015-11-18 | |
| US62/256,784 | 2015-11-18 | ||
| US201662404827P | 2016-10-06 | 2016-10-06 | |
| US62/404,827 | 2016-10-06 | ||
| PCT/US2016/062396 WO2017087590A1 (en) | 2015-11-18 | 2016-11-17 | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501125A JP2019501125A (ja) | 2019-01-17 |
| JP2019501125A5 true JP2019501125A5 (OSRAM) | 2019-12-26 |
| JP6843135B2 JP6843135B2 (ja) | 2021-03-17 |
Family
ID=57472068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018525654A Active JP6843135B2 (ja) | 2015-11-18 | 2016-11-17 | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10479793B2 (OSRAM) |
| EP (1) | EP3377496B1 (OSRAM) |
| JP (1) | JP6843135B2 (OSRAM) |
| KR (1) | KR102782807B1 (OSRAM) |
| CN (1) | CN108473500B (OSRAM) |
| ES (1) | ES2828733T3 (OSRAM) |
| WO (1) | WO2017087590A1 (OSRAM) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2958391T3 (es) | 2014-11-06 | 2024-02-08 | Bial R&D Invest S A | Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos |
| SMT202400187T1 (it) | 2014-11-06 | 2024-07-09 | Bial R&D Investments S A | Pirazolo(1,5-a)pirimidine sostituite e loro utilizzo nel trattamento di disturbi medici |
| EP3215509B1 (en) | 2014-11-06 | 2020-02-26 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
| AU2017246455B2 (en) | 2016-04-06 | 2021-09-30 | Bial - R&D Investments, S.A. | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| US10787454B2 (en) | 2016-04-06 | 2020-09-29 | BIAL—BioTech Investments, Inc. | Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| WO2017176962A1 (en) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics, Inc. | Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| BR112018072552A8 (pt) * | 2016-05-05 | 2023-03-14 | Lysosomal Therapeutics Inc | Compostos de imidazo [1,2-b]piridazinas e imidazo [1,5-b] piridazinas substituídas, composição farmacêutica que os compreende e seu uso no tratamento de distúrbios médicos |
| US10836770B2 (en) | 2016-10-07 | 2020-11-17 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INF alpha responses |
| JP7012082B2 (ja) * | 2016-11-17 | 2022-01-27 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｌ－１２、ｉｌ－２３および／またはｉｆｎ－アルファのイミダゾピリダジン調節剤 |
| WO2019023468A1 (en) * | 2017-07-28 | 2019-01-31 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
| AR117398A1 (es) | 2018-03-12 | 2021-08-04 | Abbvie Inc | Inhibidores de la señalización mediada por tirosina cinasa 2 |
| EP3849981B1 (en) | 2018-09-10 | 2023-02-01 | Eli Lilly and Company | Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus |
| FI3870579T3 (fi) | 2018-10-22 | 2025-01-02 | Alumis Inc | Tyk2-inhibiittoreita ja niiden käyttöjä |
| TWI800696B (zh) | 2018-12-10 | 2023-05-01 | 美商美國禮來大藥廠 | 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物 |
| TWI752400B (zh) * | 2019-01-07 | 2022-01-11 | 美商美國禮來大藥廠 | Il-17a抑制劑 |
| CA3126034A1 (en) * | 2019-01-23 | 2020-07-30 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| KR20210124409A (ko) * | 2019-02-07 | 2021-10-14 | 벤틱스 바이오사이언스, 인크. | Tyk2 슈도키나제 리간드 |
| ES2987809T3 (es) * | 2019-03-05 | 2024-11-18 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de las respuestas de IL-12, IL-23 y/o IFN alfa |
| US20220177486A1 (en) * | 2019-03-11 | 2022-06-09 | Esker Therapeutics, Inc. | Tyk2 inhibitors and uses thereof |
| AR121251A1 (es) | 2020-02-12 | 2022-05-04 | Lilly Co Eli | Compuestos de 7-(metilamino)pirazolo[1,5-a]pirimidina-3-carboxamida |
| EP4143195B1 (en) * | 2020-04-30 | 2025-05-21 | Janssen Pharmaceutica NV | Imidazopyridazines as modulators of il-17 |
| MX2022013650A (es) * | 2020-04-30 | 2023-02-01 | Janssen Pharmaceutica Nv | Imidazopirimidinas como moduladores de il-17. |
| EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
| CN115916207A (zh) * | 2020-08-20 | 2023-04-04 | 轶诺(浙江)药业有限公司 | 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途 |
| AU2021345181A1 (en) * | 2020-09-16 | 2023-05-04 | Alumis Inc | Tyk2 inhibitors and uses thereof |
| CA3213816A1 (en) | 2021-03-16 | 2022-09-22 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Amino heteroaryl compounds and compositions |
| EP4423086A1 (en) | 2021-10-25 | 2024-09-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| CN118580191A (zh) * | 2022-01-28 | 2024-09-03 | 和记黄埔医药（上海）有限公司 | 用于制备咪唑并[1,2-b]哒嗪类化合物的中间体 |
| WO2025168035A1 (zh) * | 2024-02-07 | 2025-08-14 | 合肥羿科医药有限公司 | 杂环类化合物、其药物组合物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7176214B2 (en) | 2003-05-21 | 2007-02-13 | Bristol-Myers Squibb Company | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| US8188272B2 (en) | 2007-03-21 | 2012-05-29 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US20110046127A1 (en) * | 2007-11-08 | 2011-02-24 | Paolo Pevarello | Imidazopyridazines for Use as Protein Kinase Inhibitors |
| US8389527B2 (en) * | 2008-02-06 | 2013-03-05 | Bristol-Myers Squibb Company | Substituted imidazopyridazines useful as kinase inhibitors |
| TWI491610B (zh) | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
| US9957271B2 (en) | 2011-10-20 | 2018-05-01 | Glaxosmithkline Llc | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
| US8969565B2 (en) * | 2012-03-09 | 2015-03-03 | Lexicon Pharmaceuticals, Inc. | Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use |
| ES2702126T3 (es) * | 2013-12-10 | 2019-02-27 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa |
-
2016
- 2016-11-17 JP JP2018525654A patent/JP6843135B2/ja active Active
- 2016-11-17 ES ES16805656T patent/ES2828733T3/es active Active
- 2016-11-17 EP EP16805656.2A patent/EP3377496B1/en active Active
- 2016-11-17 WO PCT/US2016/062396 patent/WO2017087590A1/en not_active Ceased
- 2016-11-17 US US15/776,094 patent/US10479793B2/en active Active
- 2016-11-17 CN CN201680079065.7A patent/CN108473500B/zh active Active
- 2016-11-17 KR KR1020187016633A patent/KR102782807B1/ko active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019501125A5 (OSRAM) | ||
| JP2019530699A5 (OSRAM) | ||
| CY1123994T1 (el) | Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4 | |
| JP2016532715A5 (OSRAM) | ||
| JP2016516043A5 (OSRAM) | ||
| JP2016514159A5 (OSRAM) | ||
| CY1121694T1 (el) | Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4 | |
| JP2017508782A5 (OSRAM) | ||
| JP2017501237A5 (OSRAM) | ||
| JP2017071634A5 (OSRAM) | ||
| AR103064A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| EP3489232A3 (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| WO2015132799A3 (en) | Heterocyclic compounds | |
| JP2016513696A5 (OSRAM) | ||
| WO2015200481A8 (en) | Mnk inhibitors and methods related thereto | |
| PH12020500327A1 (en) | Macrocyclic mcl-1 inhibitors and methods of use | |
| JP2015522650A5 (OSRAM) | ||
| JP2014525420A5 (OSRAM) | ||
| JP2014501766A5 (OSRAM) | ||
| JP2019522055A5 (OSRAM) | ||
| JP2016507581A5 (OSRAM) | ||
| JP2015536947A5 (OSRAM) | ||
| JP2018502048A5 (OSRAM) | ||
| JP2015504081A5 (OSRAM) | ||
| JP2016506961A5 (OSRAM) |